Social networking sites like Facebook and YouTube can be powerful platforms to deliver and receive healthcare information, especially for patients and caregivers who are increasingly going online to connect and share experiences with others with similar medical issues or concerns. However, these sites may lack patient-centered information and can also be sources of misleading information that could potentially do more harm than good, according to the results of two separate social media-related studies unveiled at the American College of Gastroenterology's ACG) 76th Annual Scientific meeting in Washington, DC. In the first study, "Social Media for Esophageal Cancer Survivors, " researchers from the Mayo Clinic in Florida found that social media is an important resource for patients and their caregivers who are facing important treatment decisions after being diagnosed with esophageal cancer and managing difficult nutritional and lifestyle issues after esophageal surgery.
'Good bugs' look promising as anti-inflammatory agent for patients with ulcerative colitis, psoriasis, chronic fatigue syndrome In four different studies presented at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC, researchers explored the effectiveness of probiotics for antibiotic-associated diarrhea; as an anti-inflammatory agent for patients with ulcerative colitis, psoriasis and chronic fatigue syndrome; and for people with abdominal discomfort and bloating who have not been diagnosed with a functional bowel disorder, such as irritable bowel syndrome (IBS). These four studies will be featured during an ACG press briefing on Tuesday, November 1, 2011 entitled: "Good, Bad and Ugly Bugs: Mother Nature as a Treatment for Better Health in the GI Tract, " which will highlight new clinical science that explores the role of the "gut microbiota" - the bacterial composition of the GI tract - and the efficacy of probiotics and fecal microbiota transplantation in treating various GI conditions.
A study published Online First by Archives of Surgery, one of the JAMA/Archives journals reveals that patients with inflammatory bowel disease (IBD) undergoing surgery may be more susceptible to develop deep vein thrombosis (DVT) or pulmonary embolism (PE) following surgical procedures. Deep vein thrombosis is the formation of a blood clot in a vein deep inside the body, usually in the legs, while PE is a sudden blockage of an artery in the lung. According to background information in the article: "An increased risk of DVT and PE in patients with IBD has been evident for the past 75 years. Most work in this area has not looked specifically at patients undergoing surgery. Patients with IBD frequently require surgical intervention, and an understanding of their risk of venous thromboembolism is therefore an important issue.
Scientists have been unclear for some time about how most probiotics work. A new study has found a scientific 'design' for a probiotic that could be used to treat inflammatory bowel disease (IBD), such as Crohn's disease. The research by academics at the University of Bristol's School of Veterinary Sciences and the School of Clinical Medicine is published online in the journal PLoS ONE. Most probiotics on the market, such as Lactobacillus and Bifidobacterium, are lactic acid bacteria. Although probiotics have been shown to successfully maintain remission in IBD, evidence of their effectiveness in active disease is rare. The researchers have found that this is because an increase in iron levels, which happens during active IBD, inhibits the growth of probiotic bacteria, including Lactobacillus.
TxCell presents final positive results of the phase I/II clinical trial with antigen-specific Treg cells in Crohn's disease. At the United European Gastroenterology Week (UEGW) in Stockholm, TxCell SA presented the final positive results of its phase I/II study of OvaSave ® developed for the treatment of patients with severe chronic active Crohn's disease (CATS-1). TxCell SA is a French biotechnology company that develops Treg cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high unmet medical needs. Crohn's disease is a chronic, inflammatory bowel disease that can affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms that can be disabling. So far, existing treatments do not provide satisfactory relief to patients.